Protocol Ledger

NCT05151471 · Phase III · TERMINATED

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

Interventional Phase III clinical trial protocol NCT05151471 sponsored by Shionogi in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-01-11 Enrollment: 202 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05151471
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)202 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05151471
Protocol FieldVerified Registry Value
NCT IdentifierNCT05151471
Consolidated Lead SponsorShionogi
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment202 participants (ACTUAL)
Registered Start Date2022-01-11
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI